Trading of Insmed was halted at 10:05 AM ET due to "LULD Pause" and resumed at 10:15 AM ET.

Insmed (INSM) Stock Price, News & Analysis

Insmed logo
$144.46 +24.66 (+20.58%)
Closing price 04:00 PM Eastern
Extended Trading
$143.90 -0.56 (-0.39%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Insmed Stock (NASDAQ:INSM)

Advanced

Key Stats

Today's Range
$118.00
▼
$149.07
50-Day Range
$93.33
▼
$129.41
52-Week Range
$90.39
▼
$212.75
Volume
14.39 million shs
Average Volume
3.05 million shs
Market Capitalization
$31.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$196.52
Consensus Rating
Moderate Buy

Company Overview

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr.

Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis. Insmed also develops investigational medicines for respiratory and other serious conditions.

Insmed serves patients in the United States and select international markets. The company traces its origins to 1988 and has evolved from a specialty pharmaceutical business into a biotechnology company focused on developing therapies for conditions with limited treatment options.

AI Generated. May Contain Errors.

Insmed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

INSM MarketRank™: 
3.215357337695 of 5 stars

Insmed scored higher than 64% of companies evaluated by MarketBeat, and ranked 579th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Insmed has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 23 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Insmed has a consensus price target of $196.52, representing about 35.6% upside from its current price of $144.98.

  • Amount of Analyst Coverage

    Insmed has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Insmed's stock forecast and price target.
  • Earnings Growth

    Earnings for Insmed are expected to grow in the coming year, from ($1.86) to $0.62 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Insmed is -51.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Insmed is -51.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Insmed has a P/B Ratio of 43.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.56% of the float of Insmed has been sold short.
  • Short Interest Ratio / Days to Cover

    Insmed has a short interest ratio ("days to cover") of 3.56, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Insmed has recently increased by 4.47%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Insmed does not currently pay a dividend.

  • Dividend Growth

    Insmed does not have a long track record of dividend growth.

  • News Sentiment

    Insmed has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Insmed this week, compared to 9 articles on an average week.
  • Search Interest

    Only 16 people have searched for INSM on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,100,000.00 in company stock.

  • Percentage Held by Insiders

    2.10% of the stock of Insmed is held by insiders.

  • Percentage Held by Institutions

    Insmed has minimal institutional ownership at this time.

  • Read more about Insmed's insider trading history.
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INSM Stock News Headlines

Sanofi Weighs Takeover of US Drugmaker Insmed
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Contrasting Insmed (NASDAQ:INSM) and Applied Therapeutics (NASDAQ:APLT)
Insmed, Inc. (NASDAQ:INSM) Stock Has Average Target Price of $196.52
See More Headlines

INSM Stock Analysis - Frequently Asked Questions

Insmed's stock was trading at $174.04 at the start of the year. Since then, INSM shares have decreased by 16.7% and is now trading at $144.9750.

Insmed, Inc. (NASDAQ:INSM) posted its quarterly earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.08. Insmed's revenue was up 268.4% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional investors of Insmed include State Street Corp (2.81%), Pictet Asset Management Holding SA (0.80%), Bellevue Group AG (0.69%) and Assenagon Asset Management S.A. (0.58%). Insiders that own company stock include Melvin Md Sharoky, William Lewis, John Drayton Wise, Roger Adsett, David W J Mcgirr, Martina MD Flammer, Sara Bonstein, Elizabeth M Anderson, Leo Lee, Orlov S Nicole Schaeffer, David R Brennan, Michael Alexander Smith, Clarissa Desjardins and Clarissa Desjardins.
View institutional ownership trends
.

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Palantir Technologies (PLTR), Broadcom (AVGO) and Intel (INTC).

Company Calendar

Last Earnings
10/29/2026
Today
11/19/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INSM
CIK
1104506
Employees
1,664
Year Founded
N/A

Price Target and Rating

High Price Target
$263.00
Low Price Target
$154.00
Potential Upside/Downside
+36.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
26 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
233.00
P/E Growth
N/A
Net Income
-$1.28 billion
Net Margins
-39.85%
Pretax Margin
-39.35%
Return on Equity
-96.38%
Return on Assets
-32.55%

Debt

Debt-to-Equity Ratio
0.77
Current Ratio
2.86
Quick Ratio
2.59

Sales & Book Value

Annual Sales
$1.52 billion
Price / Sales
20.85
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.31 per share
Price / Book
43.64

Miscellaneous

Outstanding Shares
219,380,000
Free Float
214,773,000
Market Cap
$31.69 billion
Optionable
Optionable
Beta
0.83

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:INSM) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners